Objectives: Characterization of the proteasome and its stability in buffy-coat derived platelet concentrates (PCs) during storage.

Background: The proteasome plays a key role in cell homeostasis by processing misfolded or abnormal proteins and regulating the levels and activities of a high number of proteins contributing to cell cycle, survival, and proliferation. Controversial data exist, whether inhibition of the proteasome affects platelet function. Little is known about function, expression, and stability of the proteasome in PCs during storage, and the potential role of the platelet proteasome in storage lesions.

Study Design And Methods: PCs were produced by the buffy-coat method in additive solution and stored at room temperature under agitation. Platelet aggregation was monitored by light transmission aggregometry. Proteasome complexes were assessed by immunoprecipitation and immunoblotting, and proteasome activity was measured using fluorogenic substrates specific for the three different proteolytic activities over 7 days of storage.

Results: Proteasome inhibition led to a decreased platelet aggregation response after activation with collagen, ADP, TRAP-6, and thrombin. There were no changes in the expression of the catalytic active subunits as well as the proteasome activity during storage of PCs, comparing baseline and day 7.

Discussion: Platelet proteasome function is relevant for platelet aggregation in response to various agonists. The constitutive and stable expression of the active standard- and immunoproteasome in platelets makes it unlikely that loss of proteasome function is a relevant cause of storage lesions.

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.16605DOI Listing

Publication Analysis

Top Keywords

platelet proteasome
12
platelet aggregation
12
proteasome
11
platelet
9
buffy-coat derived
8
derived platelet
8
platelet concentrates
8
proteasome activity
8
aggregation response
8
proteasome function
8

Similar Publications

Background: This analysis explored real-world characteristics, treatment patterns and clinical outcomes in patients with relapsed or refractory multiple myeloma (RRMM) previously treated with lenalidomide and an anti-CD38 monoclonal antibody (mAb) and requiring subsequent treatment.

Materials And Methods: The PREAMBLE and Connect MM prospective registries of patients with multiple myeloma (MM), and the US nationwide Flatiron Health electronic health record-derived de-identified database were analysed. MM-specific treatment patterns (prior/index therapies) and outcomes (progression-free survival [PFS]/overall survival [OS]) were assessed.

View Article and Find Full Text PDF

The PROTAC selectively degrading BCL-X inhibits the growth of tumors and significantly synergizes with Paclitaxel.

Biochem Pharmacol

December 2024

Zhongshan Hospital Institute of Clinical Science, Shanghai Medical College, Fudan University, Shanghai 200032, China. Electronic address:

B-cell lymphoma extra large (BCL-X) is an important anti-apoptotic protein of BCL-2 family. It is frequently overexpressed in various hematologic and solid tumors, often positively correlated with chemotherapy resistance in tumors. However, the clinical development of the small molecule BCL-X inhibitor ABT-263 has been challenged on account of its on-target and dose-limiting toxicity.

View Article and Find Full Text PDF

Clinical application of chimeric molecules for targeted protein degradation has been limited by unfavorable drug-like properties and biosafety concerns arising from nonspecific biodistribution after systemic administration. Here we develop a method to engineer platelets for degradation of either intracellular or extracellular proteins of interest (POIs) in vivo by covalently labeling heat shock protein 90 (HSP90) in platelets with a POI ligand. The degrader platelets (DePLTs) target wound areas and undergo activation.

View Article and Find Full Text PDF

Mitochondrial dysfunction in Parkinson's disease.

J Neural Transm (Vienna)

December 2024

Department of Neurology, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo, Tokyo, 113-8421, Japan.

Article Synopsis
  • The exact cause of nigral cell death in Parkinson's disease (PD) is still unclear, but research has made significant progress using models like MPTP-induced experimental parkinsonism, highlighting mitochondrial failure as a key factor in cell death.
  • Many studies have linked mitochondrial dysfunction to PD, observing deficiencies in mitochondrial complexes (specifically Complex I and III) in various tissues of PD patients, though there’s some debate on its impact in peripheral organs.
  • Mutations in mitochondrial DNA and involvement of specific genes related to mitochondrial quality control (like parkin and PINK1) further suggest that mitochondrial issues play a crucial role in the pathophysiology of PD.
View Article and Find Full Text PDF

A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma.

Ther Adv Hematol

November 2024

Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana SI-1000, Slovenia.

Background: Carfilzomib is a second-generation proteasome inhibitor (PI) used for combination therapy with dexamethasone and/or lenalidomide in patients with relapsed or refractory multiple myeloma. Reports indicate that PIs have a unique toxicity profile that includes thrombocytopenia as a hematologic adverse event; however, its occurrence has not yet been quantified systematically.

Objectives: The main objective of our systematic review and meta-analysis is to investigate the incidence of thrombocytopenia in patients with multiple myeloma after treatment with carfilzomib.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!